Biogen and UCB report post‑hoc Phase 3 data showing higher lupus response rates for dapirolizumab pegol
Biogen and UCB presented new post‑hoc analyses of the Phase 3 PHOENYCS GO trial for dapirolizumab pegol in systemic lupus erythematosus. Using the novel TRM‑SLE endpoint, 61.2% of patients on the drug achieved a response in at least half of active organ domains versus 43.2% on placebo, and 52.5% achieved response in all domains versus 36.8% on placebo. The trial also met its primary BICLA endpoint with 50% of treated patients improving versus 35% on placebo, and showed higher sustained low disease activity (24.0% vs 10.3%). Results will be presented at the ACR Convergence 2026 meeting.
Why it matters
The data suggest dapirolizumab pegol may offer a more effective treatment option for SLE, potentially increasing the drug’s commercial prospects. Investors in Biogen (BIIB) and UCB (UCB) may see valuation uplift if the results lead to regulatory approval and market adoption.
Key facts
- 1TRM‑SLE‑50 response was 61.2% with dapirolizumab pegol plus SOC versus 43.2% with placebo plus SOC. investors.biogen.com
- 2TRM‑SLE‑100 response was 52.5% with dapirolizumab pegol plus SOC versus 36.8% with placebo plus SOC. investors.biogen.com
- 3Sustained low disease activity (LLDAS) was achieved by 24.0% of dapirolizumab‑treated patients versus 10.3% of placebo patients. investors.biogen.com
- 4The primary BICLA endpoint was met with 50% of dapirolizumab‑treated patients showing improvement versus 35% on placebo. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.